AU2001273074A1 - Combinations of ssri and estrogenic agents - Google Patents
Combinations of ssri and estrogenic agentsInfo
- Publication number
- AU2001273074A1 AU2001273074A1 AU2001273074A AU7307401A AU2001273074A1 AU 2001273074 A1 AU2001273074 A1 AU 2001273074A1 AU 2001273074 A AU2001273074 A AU 2001273074A AU 7307401 A AU7307401 A AU 7307401A AU 2001273074 A1 AU2001273074 A1 AU 2001273074A1
- Authority
- AU
- Australia
- Prior art keywords
- ssri
- combinations
- estrogenic agents
- estrogenic
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21640800P | 2000-07-06 | 2000-07-06 | |
US60/216,408 | 2000-07-06 | ||
PCT/US2001/020738 WO2002003975A2 (en) | 2000-07-06 | 2001-06-29 | Combinations of ssri and estrogenic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001273074A1 true AU2001273074A1 (en) | 2002-01-21 |
Family
ID=22806947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001273074A Abandoned AU2001273074A1 (en) | 2000-07-06 | 2001-06-29 | Combinations of ssri and estrogenic agents |
Country Status (8)
Country | Link |
---|---|
EP (2) | EP1990051A1 (zh) |
JP (1) | JP2004502729A (zh) |
CN (1) | CN1452497A (zh) |
AU (1) | AU2001273074A1 (zh) |
CA (1) | CA2414938A1 (zh) |
HK (1) | HK1052877A1 (zh) |
MX (1) | MXPA03000170A (zh) |
WO (1) | WO2002003975A2 (zh) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1453521B1 (en) | 2001-12-05 | 2013-09-04 | Teva Women's Health, Inc. | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
AU2004257772B2 (en) | 2003-07-16 | 2009-12-17 | Teva Women's Health, Inc. | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
CN1993322A (zh) * | 2004-08-05 | 2007-07-04 | 惠氏公司 | 哌多昔芬盐酸盐一水合物的结晶多晶型物 |
US20070111975A1 (en) | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
CA2601898A1 (en) * | 2005-03-31 | 2006-10-05 | Wyeth | O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof |
US9486419B2 (en) * | 2013-04-17 | 2016-11-08 | Ariel-University Research And Development Company | CB2 receptor ligands for the treatment of psychiatric disorders |
KR20180071274A (ko) | 2015-10-01 | 2018-06-27 | 올레마 파마슈티컬스 인코포레이티드 | 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물 |
LT3386500T (lt) | 2015-12-09 | 2022-12-27 | The Board Of Trustees Of The University Of Illinois | Selektyvūs estrogenų receptorių slopintojai benzotiofeno pagrindu |
WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
EP3454856A4 (en) | 2016-05-10 | 2019-12-25 | C4 Therapeutics, Inc. | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
AU2017290748A1 (en) | 2016-07-01 | 2019-01-17 | G1 Therapeutics, Inc. | Pyrimidine-based antiproliferative agents |
WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
TWI823845B (zh) | 2017-01-06 | 2023-12-01 | 美商G1治療公司 | 用於治療癌症的組合療法 |
AU2018217809A1 (en) | 2017-02-10 | 2019-08-22 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
NZ759691A (en) | 2017-06-29 | 2023-05-26 | G1 Therapeutics Inc | Morphic forms of git38 and methods of manufacture thereof |
WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
WO2024097989A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein degraders |
WO2024097980A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein inhibitors |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2194984C (en) * | 1994-07-26 | 2002-07-02 | John Eugene Macor | 4-indole derivatives as serotonin agonists and antagonists |
TW397821B (en) | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
US5880137A (en) | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
US5780497A (en) | 1996-04-19 | 1998-07-14 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
PT802183E (pt) * | 1996-04-19 | 2002-03-28 | American Home Prod | Agentes estrogenicos |
ES2281937T3 (es) | 1997-10-15 | 2007-10-01 | Wyeth | Nuevas ariloxi-alquil-dialquilaminas. |
EP1080073A1 (en) * | 1998-05-15 | 2001-03-07 | American Home Products Corporation | Compositions comprising 2-phenyl-indole compounds and estrogen formulations |
-
2001
- 2001-06-29 EP EP08103937A patent/EP1990051A1/en not_active Withdrawn
- 2001-06-29 JP JP2002508430A patent/JP2004502729A/ja active Pending
- 2001-06-29 AU AU2001273074A patent/AU2001273074A1/en not_active Abandoned
- 2001-06-29 EP EP01952310A patent/EP1311293A2/en not_active Ceased
- 2001-06-29 CA CA002414938A patent/CA2414938A1/en not_active Abandoned
- 2001-06-29 MX MXPA03000170A patent/MXPA03000170A/es not_active Application Discontinuation
- 2001-06-29 WO PCT/US2001/020738 patent/WO2002003975A2/en active Search and Examination
- 2001-06-29 CN CN01815252A patent/CN1452497A/zh active Pending
-
2003
- 2003-07-16 HK HK03105156.6A patent/HK1052877A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP1311293A2 (en) | 2003-05-21 |
MXPA03000170A (es) | 2003-05-27 |
CN1452497A (zh) | 2003-10-29 |
EP1990051A1 (en) | 2008-11-12 |
JP2004502729A (ja) | 2004-01-29 |
WO2002003975A3 (en) | 2002-09-26 |
HK1052877A1 (zh) | 2003-10-03 |
WO2002003975A2 (en) | 2002-01-17 |
CA2414938A1 (en) | 2002-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001273074A1 (en) | Combinations of ssri and estrogenic agents | |
AU2001285020A1 (en) | P97-active agent conjugates and their methods of use | |
AU2001245401A1 (en) | Hydrazones and analogs as cholesterol lowering agents | |
AU2002225954A1 (en) | Dipeptidylpeptidases and methods of use | |
AU2778801A (en) | Antisense compositions and methods | |
AU2468401A (en) | Underreamer and method of use | |
AU2002314466A1 (en) | Withasol and methods of use | |
AU2001234437A1 (en) | Deicing compositions and methods of use | |
AU2001281140A1 (en) | Anti-plasmodium compositions and methods of use | |
AU3622600A (en) | Metalloproteinases and methods of use therefor | |
AU2001245987A1 (en) | Compositions and methods for gene therapy | |
AU2001271785A1 (en) | Combinations of statins, estrogenic agents and optionally estrogens | |
AU2001273131A1 (en) | Methods of inhibiting uterotrophic effects of estrogenic agents | |
GB0022710D0 (en) | Dispenser and method of use | |
AU2002213346A1 (en) | Osteopontin-coated surfaces and methods of use | |
AU2001288972A1 (en) | Antipsychotic sulfonamide-heterocycles, and methods of use thereof | |
WO2001091700A8 (en) | Composition and method for enhancing elasticity of tissue | |
AU2001273052A1 (en) | Antifungal compounds and methods of use | |
AU2002363938A1 (en) | Methods and use of motoneuronotropic factors | |
AU2001241771A1 (en) | Use of avocado-soybean unsaponifiable preparations | |
AU2001264863A1 (en) | Preparation of fagopyritols and uses therefor | |
AU2001259441A1 (en) | Cellular regulators of infectious agents and methods of use | |
AU2001261496A1 (en) | Luxo-sigma54 interactions and methods of use | |
AU2001249692A1 (en) | Phospholipid scramblases and methods of use thereof | |
EP1263935A4 (en) | SCYTONEMINE AND METHODS OF USE |